GYRE — GYRE THERAPEUTICS, INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 1124105 ·
Last close
$6.08
Market Cap
$589.93M
52W High
$8.20
52W Low
$5.44
ADV30
94,960
Next earnings
2026-05-07
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 22,519,000 21,292,000 -6,802,000 -8,691,000 162,015,000 37,501,000 25,030,000
Dec 2025 37,195,000 35,452,000 120,000 -1,723,000 166,132,000 37,070,000 23,850,000
Sep 2025 30,564,000 28,936,000 6,926,000 3,610,000 159,384,000 40,402,000 21,969,000
Jun 2025 26,771,000 25,620,000 2,172,000 442,000 152,646,000 36,491,000 23,203,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,010,000
Investing CF
$-474,000
Financing CF
$24,378,000
CapEx
$-1,923,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.01
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-68,426,000
Inventory
$10,171,000
Receivables
$36,946,000
ST Investments
$15,355,000
EBIT TTM
$11,491,000
Pretax Income TTM
$14,436,000
Interest Exp TTM
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$117,049,000
EBITDA
$5,073,000
Free Cash Flow
$9,599,000
Enterprise Value
$518,475,712
Total Cash
$49,808,000
Total Debt
$823,000
Shares Out
97,028,322
Trailing EPS
$-0.08
Book Value
$1.11
ROE
-3.1%
ROA
1.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 116,588,000 11,491,000 5,027,000 166,132,000 23,850,000 1,010,000
Dec 2024 105,757,000 16,229,000 12,085,000 125,406,000 27,004,000 -3,641,000
Dec 2023 113,450,000 19,213,000 -92,933,000 116,539,000 102,590,000 25,892,000
Dec 2022 102,290,000 9,203,000 2,302,000 84,753,000 12,536,000 10,677,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.06

Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $6.08 · call volume: 2 · put volume: 0

Peers — same industry

TickerNameMarket CapLastDaily %
DRUG BRIGHT MINDS BIOSCIENCES INC. $584.01M $59.52
IRWD IRONWOOD PHARMACEUTICALS INC $579.44M $3.52
ANL Adlai Nortye Ltd. $602.62M $10.26
BBOT BridgeBio Oncology Therapeutics, Inc. $615.22M $7.68
ACRS Aclaris Therapeutics, Inc. $617.31M $4.42

Recent Insider Activity

No insider activity indexed for this ticker.